M Ventures has backed the ETH Zurich spinout, which has devised a digital biomarker-driven medical device for diagnosing brain conditions such as Alzheimer's disease.
Altoida, a US-based brain health evaluation device spinout of ETH Zurich, has secured $6.3m of series A funding from investors led by M Ventures, the investment arm of health products supplier Merck Group.
The round was backed by early-stage fund Grey Sky Venture Partners as well as venture firms VI Partners, Alpana Ventures and Fyrfly Venture Partners.
Founded in 2016, Altoida has created a medical device that enables clinicians to identify digital biomarkers indicative of brain health and…
